Jupiter Neurosciences Files 8-K on Agreements and Obligations

Ticker: JUNS · Form: 8-K · Filed: 2025-10-27T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, financial-obligation, equity-sale

TL;DR

JUPITER NEUROSCIENCES (JUPITER) filed an 8-K detailing material agreements, financial obligations, and equity sales.

AI Summary

On October 24, 2025, Jupiter Neurosciences, Inc. entered into a material definitive agreement, likely related to its financial obligations. The company also reported on the creation of a direct financial obligation and unregistered sales of equity securities. This filing also includes Regulation FD disclosures and financial statements/exhibits.

Why It Matters

This 8-K filing indicates significant financial and contractual developments for Jupiter Neurosciences, Inc., potentially impacting its operational and financial standing.

Risk Assessment

Risk Level: medium — The filing details material definitive agreements, financial obligations, and unregistered equity sales, which can introduce financial and operational risks.

Key Numbers

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Jupiter Neurosciences, Inc. on October 24, 2025?

The filing indicates the entry into a material definitive agreement, but the specific details are not provided in the provided text, only that it is an 'Item Information' category.

What type of direct financial obligation was created by Jupiter Neurosciences, Inc.?

The filing states the creation of a 'Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant,' but the specific details of the obligation are not elaborated in the provided text.

When did Jupiter Neurosciences, Inc. change its name from Jupiter Orphan Therapeutics, Inc.?

The date of the name change from Jupiter Orphan Therapeutics, Inc. to Jupiter Neurosciences, Inc. was July 13, 2016.

What is the SIC code for Jupiter Neurosciences, Inc.?

The Standard Industrial Classification (SIC) code for Jupiter Neurosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

What are the key items reported in this 8-K filing?

The key items reported are: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, and Financial Statements and Exhibits.

From the Filing

0001493152-25-019783.txt : 20251027 0001493152-25-019783.hdr.sgml : 20251027 20251027172541 ACCESSION NUMBER: 0001493152-25-019783 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20251024 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251027 DATE AS OF CHANGE: 20251027 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JUPITER NEUROSCIENCES, INC. CENTRAL INDEX KEY: 0001679628 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 474828381 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41265 FILM NUMBER: 251420712 BUSINESS ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 BUSINESS PHONE: (561) 406-6154 MAIL ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 FORMER COMPANY: FORMER CONFORMED NAME: Jupiter Orphan Therapeutics, Inc. DATE OF NAME CHANGE: 20160713 8-K 1 form8-k.htm 8-K false 0001679628 0001679628 2025-10-24 2025-10-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   October 24, 2025 Date of Report (Date of earliest event reported)   JUPITER NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter)   Delaware   001-41265   47-4828381 (State or other jurisdiction   (Commission   (IRS Employer of incorporation)   File Number)   Identification No.)   1001 North US HWY 1 , Suite 504 , Jupiter , FL   33477 (Address of principal executive offices)   (Zip Code)   (561) 406-6154 Registrant’s telephone number, including area code   Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock   JUNS   Nasdaq Capital Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging Growth Company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 1.01 Entry Into a Material Definitive Agreement.   Standby Equity Purchase Agreement   On October 24, 2025, Jupiter Neurosciences, Inc., a Delaware corporation (the “Company”), entered into a Standby Equity Purchase Agreement (the “SEPA”) and a related Registration Rights Agreement (the &#822

View on Read The Filing